Clopidogrel Bisulfate, Aspirin

Description

ntroducing PharmAlliance International Labs’ Clopidogrel Bisulfate and Aspirin Tablets

Company Introduction:

PharmAlliance International Labs Private Limited welcomes you to a realm where innovation meets healthcare, dedicated to fostering wellness globally. We proudly present our groundbreaking product, Clopidogrel Bisulfate and Aspirin Tablets, crafted to deliver dual antiplatelet therapy for the prevention of cardiovascular events.

Drug Classification:

Clopidogrel Bisulfate and Aspirin Tablets belong to the class of medications known as antiplatelet agents. Clopidogrel, a thienopyridine derivative, selectively inhibits the adenosine diphosphate (ADP) receptor on platelets, while aspirin inhibits the cyclooxygenase (COX) enzyme, synergistically reducing platelet aggregation and preventing blood clot formation.

Formulations:

Each tablet of Clopidogrel Bisulfate and Aspirin contains Clopidogrel 75mg and Aspirin 150mg, providing a comprehensive approach to cardiovascular protection. These oral tablets are meticulously packaged in blister packs containing 10 tablets each, ensuring convenience and efficacy in administration.

Indications:

Clopidogrel Bisulfate and Aspirin Tablets are indicated for:

Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction, stroke, or peripheral arterial disease.

Prevention of atherothrombotic events in patients with acute coronary syndrome (unstable angina, non-ST segment elevation myocardial infarction [NSTEMI], or ST segment elevation myocardial infarction [STEMI]).

Usage:

To harness the full therapeutic potential, Clopidogrel Bisulfate and Aspirin Tablets should be taken orally once daily, preferably with food, under the guidance of a healthcare professional. Strict adherence to the prescribed dosage and administration regimen is paramount to optimizing benefits and minimizing risks.

Dosage:

The recommended dose is one tablet daily, although dosage adjustments may be necessary based on individual patient characteristics and clinical assessment. Dual antiplatelet therapy with clopidogrel and aspirin should be closely monitored and tailored to each patient’s specific needs.

Pharmacokinetics:

Clopidogrel is swiftly absorbed post-oral administration and undergoes hepatic metabolism to form its active metabolite, which effectively inhibits platelet aggregation. Aspirin, rapidly absorbed in the gastrointestinal tract, irreversibly inhibits COX enzymes, thwarting the synthesis of thromboxane A2, a potent platelet aggregator.

Pharmacodynamics:

Operating through distinct mechanisms, Clopidogrel Bisulfate and Aspirin Tablets synergistically inhibit platelet function, mitigating the risk of thrombotic events, including myocardial infarction, stroke, and cardiovascular death.

Side Effects:

While generally well-tolerated, common side effects may include gastrointestinal symptoms such as abdominal pain, dyspepsia, and gastritis. Bleeding, encompassing gastrointestinal and intracranial hemorrhage, is a potential adverse effect and may occur with prolonged usage. Rare but serious adverse effects such as thrombotic thrombocytopenic purpura (TTP) and neutropenia necessitate immediate medical attention.

Experience the holistic cardiovascular protection afforded by PharmAlliance International Labs’ Clopidogrel Bisulfate and Aspirin Tablets. For further information, please do not hesitate to contact us. Your cardiac health is our unwavering commitment, and we endeavor to provide safe and effective pharmaceutical solutions tailored to your needs.